



OBG PRESENTS:

Lessons Learned Over 20 Years of Designing and Implementing Enhanced *In Situ* Bioremediation Remedies

Mark Harkness (OBG Engineers)

Lessons Learned



“We know a thing or two because we’ve seen a thing or two.”

– *Farmer’s Insurance Company*





AGENDA

Remedy Selection

Treatability Studies

Pre-design Investigation

Injection Management





REMEDY SELECTION



FS Considerations

Begin with the end in mind



DR. STEPHEN R. COVEY

“Seven Habits of Highly Effective People”



What is the Endpoint?

Rare for remedial sites to reach MCLs

Best intermediate option is to get site to MNA

If natural assimilative capacity of aquifer $>$ rate of release of VOCs into the groundwater, the net result is no plume expansion

Often requires combination of source reduction, plume treatment, and protection of sensitive receptors



Treatment Train Approach

Source Reduction → Plume treatment → MNA

Excavation → EISB → MNA

EISB → EISB → MNA

ISCO → EISB → MNA

Thermal → EISB → MNA



When we try
to fight
mother
nature, we
usually lose...

Match the remedy to the natural environment


Anaerobic aquifers → EISB or ISCR (not ISCO)

Aerobic aquifers → more options (but avoid EISB in high-flow situations)

Low permeability soils → modify injection method and use solid amendments



When we try
to fight
mother
nature, we
usually lose...



Choosing the
wrong remedy
is like trying to
push a big rock
up a hill



When we try
to fight
mother
nature, we
usually lose...

Match the remedy to the natural environment

Anaerobic aquifers → EISB or ISCR (not ISCO)

Aerobic aquifers → more options (but avoid EISB in high-flow situations)

Low permeability soils → modify injection method and use solid amendments



Treatment Train Approach

Source Reduction → Plume treatment → MNA

Excavation → EISB → MNA

EISB → EISB → MNA

ISCO → EISB → MNA

Thermal → EISB → MNA



Application of EISB to Source Areas



Outdated thinking based on early application of EISB to plumes

Bacteria activity will be inhibited in presence of DNAPL



Can We Treat DNAPL Source Areas Using EISB?




Key Question: Can EISB result in effective and quantifiable treatment of chlorinated solvent DNAPL source areas?




BENEFIT 1

Methane Inhibition in the Presence of DNAPL



BENEFIT 2

DNAPL Dissolution Enhancement



ITRC, In Situ Bioremediation of Chlorinated Ethene: DNAPL Source Zones. June 2008.



BENEFIT 2


DNAPL
Dissolution
Enhancement

How much should we expect?

	Compound	
	PCE	TCE
Solubility (mg/L)	150	1,100
Enhancement in Lab	5-15	~2
Enhancement in Field	3-5	~1.5




Comparison of Mass Removal over Time




BENEFIT 3

Partitioning Donor Behavior (EVO)



Three days



Six days



Treatment Train Approach

Source Reduction → Plume treatment → MNA

Excavation → EISB → MNA

EISB → EISB → MNA

ISCO → EISB → MNA

Thermal → EISB → MNA



There are issues with ISCO & EISB due to residuals
left in soil



Impact of ISCO on EISB


Permanganate oxidation forms MnO₂ by-product




- MnO₂ can act as an electron acceptor at higher ORP/Eh than chlorinated ethenes
- Reduction of MnO₂ consumes carbon substrate
- Reductive dechlorination will be delayed by residual MnO₂



Sequential Consumption of Electron Acceptors



MnO₂ – Delay in Redox Reduction and Increase in Substrate Demand





LAB TREATABILITY TESTING





What is a treatability test?

- Laboratory based “bench-scale” testing
- Typically 6 -12 months long
- Uses site soil, sediment or rock and groundwater, typically in batch bottles
- Column studies can also be performed, but are much less common
- Used to assess biodegradation potential under site-specific conditions

Why do Treatability Studies?



Relatively low cost



Test multiple variables at the same time – narrows potential options prior to going to the field



Identify potential complications and address them before they cause problems in the field



Obtain regulator or client buy-in prior to investing in field-scale tests

TYPICAL COST

Lab treatability study - \$10-30 K

Field pilot test - \$100-300 K



Specific Objectives of Biotreatability Studies

Verify overall performance

Test various electron donors

Identify inhibitory factors and evaluate solutions


Evaluate benefits of bioaugmentation

Evaluate benefits of nutrients

Confirm reaction end products



Biotreatability Study Design



Design of Experiment (DoE) approach reduces the number of bottles and provides best way to do statistical analysis







Ode to Lab Treatability Studies

TABLE 1: OVERALL STUDY DESIGN

Treatment	Mineral Media	Bioaug	Nutrients
Control	X	X	Standard N&P
Slow Release 1 Level 1	X	X	Slow-release
Slow Release 2 Level 2	X	X	Slow-release
Slow Release 3 Level 3	X	X	Slow-release



Ode to Lab Treatability Studies





Importance of Sample Collection

- The sample is “alive”
- Collect using core tube
- Minimize field disturbance
- Cap and seal ends, store on ice
- Ship to lab quickly
- Lab should transfer soil to glass container and store under anaerobic conditions
- Set up study quickly
- Understand that soil has a “shelf life”

CONFIDENTIAL – FOR INTERNAL USE ONLY






PRE-DESIGN SITE INVESTIGATION



PRE-DESIGN SITE INVESTIGATION

Example




Investments in site investigation can support remedy savings, to a point.



PRE-DESIGN SITE INVESTIGATION

Example

Source
treatment
area




Biobarriers



PRE-DESIGN SITE INVESTIGATION

Example



PRE-DESIGN SITE INVESTIGATION

Example



Site investigation program cost for 20 Geoprobe points to 65 feet with field GC and lab confirmations = \$61,347




Unit cost savings by eliminating one injection location with 3 injection intervals and injection of treatment chemicals = \$16,000

Elimination of 4 well locations results in positive cost benefit



PRE-DESIGN SITE INVESTIGATION

Example



PRE-DESIGN SITE INVESTIGATION

Example



Pre-design investigation resulted in an improved, more focused treatment strategy



Plume volume estimate shrunk by 35 to 40%



Eliminated 56 of 183 well screens (30% reduction)



Relocation of 15 well screens for better coverage

Cost reduction of \$288,000 for investment of \$61,300





INJECTION MANAGEMENT



INJECTION MANAGEMENT

Lessons Learned from Direct-Push Injection of In Situ Reagents

This Session - 9:40-10:05 am

M. McCaughey, R. Oesterreich, P. Jin, M. Gentile, A.
Pennington, S. Burnell, M. Chalfant, and J. McDonough.
Ryan Oesterreich (Arcadis/USA)





OBG | THERE'S A WAY

Thank you!

Mark.Harkness@obg.com